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α-Vinylic amino acids: occurrence, asymmetric synthesis, and 
biochemical mechanisms
David B. Berkowitz, Bradley D. Charette, Kannan R. Karukurichi, and Jill M. McFadden
Department of Chemistry, University of Nebraska–Lincoln, Lincoln, NE 68588-0304
Abstract — This report presents an overview of the family of naturally occurring “vinylic” 
amino acids, namely those that feature a C–C double bond directly attached to the α-carbon, 
along the side chain. Strategies that have been brought to bear on the stereocontrolled 
synthesis of these olefi nic amino acids are surveyed. The mechanistic diversity by which 
such “vinylic triggers” can be actuated in a PLP (pyridoxal phosphate) enzyme active site is 
then highlighted by discussion of vinylglycine (VG), its substituted congeners, particularly 
AVG [4E-(2′-aminoethoxy)vinylglycine], and a naturally occurring VG-progenitor, SMM 
[(S)-methylmethionine]. 
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1. Introduction
Enzymes that depend on the cofactor, pyridoxal phosphate 
(PLP),1 generally serve to transform amino acids. In contrast 
to the amino acid decarboxylases (e.g., L-DOPA or L-ornithine 
decarboxylase) and the retroaldolases (e.g., serine hydroxy-
methyltransferase), most classes of PLP enzymes initiate their 
chemistry by abstracting the α-proton of the substrate amino 
acid. These include: (i) transaminases, such as γ-aminobutyr-
ate (GABA) transaminase, that interconvert amino acids and 
their corresponding α-keto acids; (ii) racemases, such as ala-
nine racemase, a key bacterial cell wall biosynthetic enzyme; 
(iii) β-eliminase or replacement enzymes, such as cystathio-
nine β-synthase (CBS), a key human transsulfuration enzyme, 
and (iv) γ-eliminase or replacement enzymes, such as cysta-
thionine γ-lyase (CGL), the next enzyme in this pathway. For 
the latter enzymatic class, a subsequent β-deprotonation is 
also necessary. The eliminase or replacement enzymes, then 
subsequently expel the leaving group attached to the β- or γ-
carbon, respectively, using the electron density imported into 
the PLP π-system from the deprotonation step(s).
As can be seen in Figure 1, α-vinylic amino acids feature 
a C–C double bond directly attached to the α-carbon atom. 
If an α-proton is also present, one may regard these as vi-
nylglycine congeners. For such amino acids, removal of the 
α-proton has the effect of conjugating the otherwise isolat-
ed vinyl group with the extended π-system of the cofactor. 
This can lead to a more reactive intermediate, as will be dis-
cussed later. At the outset, it suffi ces to note the correspon-
dence between the initial step in the mechanism of many 
PLP enzymes and the initial step in the unmasking of the vi-
nyl group in this class of amino acids. 
Figure 1.  PLP enzymes that α-deprotonate and α-vinylic amino acid structure. 
2. Natural occurrence
Perhaps, seeking to capitalize on the latent reactivity of the 
double bond, in some cases, perhaps benefi ting from the “con-
formational constraint” afforded by the sp2-alkene geometry, 
in others, Nature has evolved a class of α-vinylic amino ac-
ids—the subject of this Report. Note that the discussion here-
in will be restricted to the class of vinylic amino acids bearing 
unsaturation directly attached to the α-center, and also bear-
ing an α-proton. Quaternary α-vinylic amino acids represent 
both a structurally and functionally distinct amino acid class, 
as these do not possess an α-proton and, thus target a different 
set of PLP enzymes (vide supra).2, 3, 4, 5, 6, & 7
2.1. Vinylglycine
Among the naturally occurring α-vinylic amino acids, 
the simplest and probably most widely studied member of 
the family is α-vinylglycine (VG) itself. The D-antipode is 
known to be produced by the mushroom, Rhodophyllus nid-
orosus.8 On the other hand, the antipode, L-VG is generated 
in a variety of PLP enzyme active sites. For example, L-VG 
is observed as a mechanistic intermediate to α-ketobutyrate 
in the reaction catalyzed by cystathionine γ-synthase,9 and in 
the conversion of homoserine to threonine by threonine syn-
thetase.10 L-VG is a substrate for sheep liver threonine de-
aminase,11 E. coli tryptophan synthetase,12 rat liver cysta-
thionine γ-lyase and Salmonella typhimerium cystathionine 
γ-synthetase.13 L-VG also reportedly undergoes deamination 
and γ-addition by L-methionine γ-lyase.14 & 15 D-VG is a sub-
strate (processed to α-ketobutyrate and NH3), but not inhibi-
tor, of ACC deaminase, while L-VG is neither (Fig. 2).16 
Figure 2. Naturally occurring vinylglycine antipodes. 
Perhaps because of its small side chain, the parent member of 
the family displays a rather broad spectrum of transaminase 
inhibition. Thus, (dl)-VG inhibits aspartate aminotransfer-
ase,17 & 18 D-amino acid transaminase,13 and kynurenine ami-
notransferase,19 whereas the D-isomer has been specifi cally 
shown to inhibit rat hepatic alanine aminotransferase.18
Interestingly, it appears that one can also tap into radical based 
inactivation pathways with VG. Thus, the fl avoenzyme L-ami-
no acid oxidase is presumably inactivated by the L-antipode, 
though, to the best of our knowledge, these studies have only 
been performed on the racemate.20 In a complementary study, 
Vederas and Zabriskie have shown that the tripeptide D-Phe-L-
Phe-D-VG inactivates peptide α-hydroxylating enzyme, an en-
zyme responsible for installing C-terminal carboxamide func-
tionality.21 & 22 Interestingly, inversion of the stereocenter of 
the terminal amino acid to L-VG yields a tripeptide that dis-
plays only reversible inhibition of the enzyme.
L-VG also irreversibly inactivates the nifS gene product, an 
enzyme that releases S from L-cysteine for Fe–S cluster bio-
synthesis.23 Finally, the best characterization of the mode of 
inactivation of a PLP enzyme by VG is for the enzyme ACC 
(1-aminocyclopropane-1-carboxylate) synthase.24, 25, 26, 27, & 28 
This is discussed in considerable detail in Section 4.
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2.2. β-Substituted
Three naturally occurring β-substituted vinylglycine analogues 
are described in the literature (Fig. 3). L-3,4-Didehydrovaline 
2 is a constituent of the 13-membered macrocycle phomopsin 
A, isolated from Phomopsis leptostromifrmis.29 & 30 β-Methy-
lene-L-norvaline 3 has been isolated from both Lactarius hel-
vus31 and Philadelphus coronarius.32 Finally, β-methylene-L-
norleucine 4 is found in isolates from Amanita vaginata.33 
Figure 3. β-Substituted vinylglycines from natural sources. 
2.3. γ-Substituted
As is shown in Figure 4, there is a notable spectrum of γ-sub-
stituted vinylglycine-based natural products. Several of these 
have an interesting enol ether substructure that appears to in-
fl uence the mechanism (vide infra). 
2.3.1. MVG
The fi rst vinylic amino acid bearing an enol ether functionality 
to be characterized was 4E-methoxyvinylglycine 5 (MVG), iso-
lated from Pseudomonas aeruginosa.34 and 35 Interestingly, this 
vinyl ether serves as a substrate of methionine γ-lyase,15 and 
both a substrate and an inhibitor of tryptophan synthase.36 & 12 
In pioneering work, Rando showed that 5 inactivates porcine as-
partate aminotransferase.37 & 38 Similar observations were made 
with the rat enzyme.18 E-MVG has been reported to inhibit por-
phobilinogen synthase,39 as well as δ-aminolevulinic acid syn-
thetase and dehydratase from rat tissue.40 As it turns out, the Z-
isomer of MVG, though apparently not naturally occurring, is 
one of the most effective inhibitors of methionine adenosyltrans-
ferase.41 & 42 This is discussed in more detail in Section 4.
2.3.2. AVG
The E-isomer of 4-(2′-aminoethoxy)vinylglycine, AVG 6 can 
be biosynthesized in Streptomyces.43 Like MVG, AVG bears 
an oxygen at the γ-carbon, and so resembles methionine. How-
ever, unlike MVG, AVG has a more extended side chain, ter-
minating is an ammonium group, that is positively charged at 
physiological pH. This ammonium group is positionally juxta-
posed on the cysteine-derived ammonium group of l, L-cysta-
thionine. Whereas Z-MVG serves as an apparent L-methionine 
isostere in the methionine adenosyltransferase active site, un-
surprisingly, AVG was found to inhibit cystathionine process-
ing enzymes including cystathionine β-lyase,44 & 43 and human 
recombinant cystathionine γ-lyase.45 AVG also inhibits cysta-
lysin,46 the enzyme that catalyzes the β-elimination of cyste-
ine to pyruvate, ammonia, and H2S.
Most importantly, the positively charged ammonium group 
along the methionine-like side chain engenders AVG with a 
structural similarity to SAM. Indeed, AVG is a well-known 
inhibitor of 1-aminocyclopropane-1-carboxylate (ACC) syn-
thase, the PLP enzyme that converts SAM into ACC. Since this 
serves as a key step in plant ethylene biosynthesis, AVG has 
seen wide application as a fruit ripening inhibitor. The ACC 
synthase inhibitory behavior of AVG has been characterized 
with the enzymes from both red tomato and apple.47, 48, & 49
2.3.3. Rhizobitoxine
The third and most structurally complex member of the enol 
ether subfamily of the α-vinylic amino acids is rhizobitoxine 
7. The backbone of this amino acid superimposes upon that 
of AVG, but a second stereocenter is added precisely where 
the second stereocenter in cystathionine is located. Only here, 
a hydroxymethyl group is appended to this stereocenter, in 
place of the cystathionine carboxylate group, and with the ap-
propriate stereochemistry to mimic this amino acid.
Rhizobitoxine is produced by symbiotic bacteria, such as Rhi-
zobium japonicum,50, 51, & 52 and also by the plant pathogen, 
Pseudomonas andropogonis.53 Presumably, at least in part be-
cause of its close structural resemblance to cystathionine, rhi-
Figure 4. γ-Substituted vinylic amino acids. 
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zobitoxine inhibits cystathionine β-lyase, from both Salmonel-
la typhimurium and spinach.50 & 54 Rhizobitoxine also decreases 
hydrogenase biosynthesis in Bradyrhizobium japonicum,55 by 
inhibiting depression of the hydrogenase gene. However, as this 
effect is reversed by the addition of methionine, this may be a 
downstream consequence of rhizobitoxine’s inhibition of me-
thionine biosynthesis at the cystathionine β-lyase stage.
Probably the most important activity of rhizobitoxine resides 
in its ability, analogous to AVG, to inhibit ACC synthase.56 
This is one of the two important mechanisms by which symbi-
otic bacteria are known to inhibit ethylene biosynthesis in the 
roots of their host legumes.57 The other is through the activi-
ty of bacterial SAM deaminase, which rather than inhibit the 
conversion of SAM to ACC, simply siphons off SAM by oxi-
dative deamination. As the plant hormone, ethylene, is known 
to inhibit root nodulation, rhizobia have presumably evolved 
these interesting mechanisms for ethylene biosynthesis inhi-
bition to insure a favorable nodulation environment for their 
survival. As there are agricultural biotechnological interests in 
nitrogen fi xation, rhizobitoxine and/or the rhizobitoxine bio-
synthetic machinery may have future applications here.
2.3.4. Other γ-substituted VG analogues
A naturally occurring phosphonate analogue of homoserine 
phosphate, Z-2-amino-5-phosphono-3-pentenoic acid 9 (Z-
APPA) is a constituent of the dipeptide rhizocticins,58 & 59 and 
tripeptide plumbemycins.60 & 59 One might predict, that the free 
amino acid, APPA is active against PLP enzymes that normally 
take L-homoserine phosphate as a substrate. This includes cys-
tathionine γ-synthase (synthesize cystathionine from cysteine 
and homoserine phosphate) for which E-APPA is a tight-bind-
ing reversible inhibitor (see Section 4 for further discussion).61 
Threonine synthase is a PLP enzyme that performs a β,γ-phos-
phate elimination/β-hydration sequence from L-homoserine 
phosphate. The threonine synthase enzyme from E. coli is ir-
reversibly inactivated by both the E- and Z-isomers of APPA.62
E-3,4-Dehydro-2-aminopimelic acid 8 has been isolated from 
Aspenium unilaterale.63 & 64 Z-3,5-Hexadienoic acid 10 (buta-
dienylglycine) is found in the defensive secretions of Dorypho-
rina beetles,65 Platyphora kollari beetles,66 and in the fruiting 
bodies of Clavulinopsis helvola.67 Amino acids 11 and 12 were 
found as amino acid constituents of the dipeptide trypsin in-
hibitor, radiosumin A, biosynthesized by the cyanobacterium 
Plectonema radiosum.68 & 69 The two differ only through N-
acetylation at the 8-position in compound 12, and the unsatura-
tion across the 5,6-carbons in compound 11. The very closely 
related amino acids, 13 and 14, are the constituents of a similar 
dipeptide trypsin inhibitor, later identifi ed in the cyanobacteri-
um Microcystis aeruginosa, and named radiosumin B.70
2.4. β,γ-Disubstituted
Densely functionalized vinylic amino acids 15 and 16, differ-
ing only in the oxidation state of the β-appendage, were isolat-
ed together from the mushroom Bankera fulgineoalba.71 The 
novel chlorinated glutamate analogue, 17, is found in isolates 
of Streptomyces viridogenes.72 The function of these interest-
ing α-vinylic amino acids remains to be elucidated (Fig. 5). 
Figure 5. β,γ-Substituted vinylic amino acids. 
3. Asymmetric synthesis
Owing to its interesting enzyme-inhibitory activity and its po-
tential as a synthon,73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 
88, 89, & 90 vinylglycine has attracted the attention of synthetic 
chemists. Hence, a variety of asymmetric synthetic methodol-
ogies to access D- and L-vinylglycine are available in the cur-
rent literature. A compilation of known stereocontrolled ap-
proaches for this important target is presented below.
3.1. Chiron-based entries into vinylglycine
Afzali-Ardakani and Rapoport reported the fi rst synthesis of 
vinylglycine from L-methionine.91 In this synthesis, controlled 
oxidation to the sulfoxide, followed by pyrolysis under Kugel-
rohr conditions, allowed them to distill over the protected vi-
nylglycine product as it forms. Deprotection produces L-vinyl-
glycine in 99% enantiomeric excess (Scheme 1). 
Scheme 1. Rapoport’s sulfoxide pyrolysis entry. 
A photofragmentation approach, again starting from L-methi-
onine has been developed by Griesbeck et al.92 & 93 Irradiation 
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of the sulfoxide(s) 21a/b at 300 nm in acetonitrile gives meth-
yl N-phthaloyL-L-vinylglycinate 24. This protocol encoun-
tered problems due to side reactions when substrate concentra-
tions above 10 mM were used. This limitation was overcome 
by photolyzing the ring-opened product of L-homoserine lac-
tone with HBr or HCl (Scheme 2). 
Scheme 2. Griesbeck’s photofragmentation route from L-methionine. 
Berkowitz et al. also developed a practical route to L-vinylgly-
cine from homoserine lactone, in this case, via organoselenium 
chemistry (Scheme 3).94 Thus, opening of N-Boc-protected L-
homoserine lactone 26 with phenylselenolate anion occurs ex-
clusively at the softer γ-carbon, allowing for subsequent instal-
lation of the double bond via syn elimination of the selenoxide. 
Scheme 3. Berkowitz et al.’s use of phenylselenolate lactone-opening chemistry. 
A route developed by Pellicciari et al.,95 likewise employs L-
homoserine as the chiron, and also avails itself of selenox-
ide elimination chemistry. In this route, however, rather than 
use nucleophilic lactone opening for the introduction of sele-
nium, a modifi ed Mitsunobu protocol developed by Grieco96, 
97, & 98 was exploited (Scheme 4). 
There are two classic vinylglycine syntheses that employ L-
glutamate as the chiron. Early on, Hanessian developed an el-
egant route based upon a Cu(II)/Pb(IV)-mediated oxidative 
decarboxylation of the γ-carboxylate to introduce the vinyl 
Scheme 5. Hanessian’s oxidative decarboxylation of L-glutamate. 
group (Scheme 5).99 Townsend et al. later reported improve-
ments in the procedure, based upon the use of benzyl and 
benzhydryl esters to facilitate the purifi cation (crystalliza-
tion), deprotection, and assessment of enantiomeric purity.84 
A complementary route from L-glutamate exploits the Barton 
decarboxylation of N-hydroxyl-2-chalcogenopyridone esters 
(Scheme 6).100 The photochemical decarboxylative rearrange-
ment of ester 32 provides the γ-arylselenide 33 directly. This in-
Scheme 4. Arylselenium introduction via the Grieco protocol. 
Scheme 6. Decarboxylative introduction of selenium via a Barton ester. 
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termediate is primed for introduction of the α-vinyl group via ox-
idative pyrolysis of the pyridyl selenide. One obtains protected L-
vinylglycine in acceptable yield and with uncompromised ee. 
Diaz-de-Villegas et al.101 have achieved the synthesis of L-vi-
nylglycine from D-glyceraldehyde. This synthesis utilizes ste-
reochemical communication, wherein the original, chiral pool-
derived stereocenter is used to induce stereochemistry in an 
adjacent center, and is then excised oxidatively in unveiling the 
α-carboxyl group. A highly diastereoselective vinyl-Grignard 
addition to N-benzyl-2,3-O-isopropylidene-D-glyceraldimine is 
the hallmark of this synthesis (Scheme 7). Note that the diaste-
reopreference observed is in accordance with the Felkin-Anh 
model. However, for such cyclic systems, the authors suggest 
that other transition state models might also be considered.102 
L-Serine also serves as a chiral pool precursor to L-vinylgly-
cine, via methylenation protocols, though here extra care must 
be taken to minimize racemization of the intermediate alde-
hyde. Thus, Lajoie et al.103 report that application of the Peter-
son olefi nation to a suitably protected L-serinal derivative leads 
to L-vinylglycine in high ee (Scheme 8). Whereas attempts to 
induce conversion of the intermediate β-hydroxysilane 40 to 
the alkene with base failed, acidic conditions not only succeed-
ed, but also permitted concomitant Cbz and OBO orthoester 
deprotection. Note that other olefi nation methods examined 
generally gave a signifi cant degree of racemization. In a simi-
lar vein, Beaulieu et al.104 used methylenation of the Garner al-
dehyde to access vinylglycine, albeit in modest yields and ee. 
Scheme 8. Lajoie’s Peterson olefi nation route from L-serine. 
3.2. Enzymatic kinetic resolutions to VG
In a couple of instances, enzymatic kinetic resolution has been 
applied to VG targets. Very early on, Helboe et al.105 subjected 
(dl)-vinylglycine, obtained via a Strecker synthesis with acro-
lein, to fermentation with baker’s yeast. D-Vinylglycine was 
obtained in 39% yield and 82% ee.
Later, Crout et al.106 described an interesting route to racemic 
vinylglycine via Neber rearrangement of N-chloroimidate 41. 
This was followed by a papain-mediated esterifi cation in a bi-
phasic system to give the individual antipodes (Scheme 9). 
Two cycles were employed to obtain the remaining D-enantio-
mer. Precise ee determinations were not reported, but the spe-
cifi c rotations reported compared well with literature values. 
Scheme 9. Neber rearrangement/papain-based kinetic resolution. 
3.3. Chiral auxiliary-based approaches to VG
Schöllkopf107 demonstrated that his widely employed chiral 
glycine enolate equivalent could be formally α-vinylated us-
ing a vinyl cation equivalent developed by Hudrlik108 (Scheme 
10). During the reaction, the condensation of the lithiated bis-
lactim ether 44 (derived from L-valine and glycine) with 2-
(tert-butyldimethylsilyl)acetaldehyde proceeded in good yield 
and with excellent cyclic stereocontrol. Subsequent treatment 
with HCl serves to effect β-elimination of the elements of 
“HO-SiR3” and unravel the bis-lactim ether auxiliary, yielding 
free D-vinylglycine of high enantiomeric purity. 
Scheme 10. Schöllkopf’s formal vinylation of his chiral glycine enolate. 
Scheme 7. Galvez’s Felkin-Anh-vinylation route from D-glyceraldehyde. 
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Duhamel et al. examined the possibility of inducing asymme-
try from an external chiral acid source, upon enolate quench-
ing. Specifi cally, the benzophenone imine-protected dehydro-
butyrine derivative 46 was deprotonated with LDA to generate 
an extended dienolate 47, that was then quenched at −70 °C 
with (R,R)-O,O′-dipivaloyltartaric acid. This kinetic quench 
produced a 42:58 ratio of α- to γ-protonation, with the former 
(deconjugation) product showing modest facial selectivity in 
favor of the D-antipode of vinylglycine (Scheme 11). 
Scheme 11. Duhamel’s chiral acid dienolate protonation approach. 
3.4. Catalytic asymmetric syntheses of vinylglycine
Trost et al.109, 110, & 111 have developed an elegant DYKAT (dy-
namic kinetic asymmetric transformation) approach to L-vinylg-
lycinol from racemic butadiene monoepoxide (Scheme 12). The 
approach hinges on a Pd(0)-mediated allylic amination reaction, 
with ligand 49 serving to provide the chiral scaffold about Pd. 
Phthalimide is used as N-nucleophile and no exogenous base is 
needed, as relief of ring strain is used to form a formally charge-
separated π-allyl-Pd intermediate, bearing a transient alkoxy 
leaving group. Presumably, this alkoxide is well suited to depro-
tonate the phthalimide nucleophile and deliver it to the append-
ed π-allyl acceptor. This highly regio- and stereoselective pro-
cess leads to the formation of (S)-2-phthalimido-3-buten-1-ol 50, 
which is then transformed to vinylglycinol in two steps.
Recently, in the context of an ISES (in situ enzymatic screen-
ing) approach to catalyst discovery,112 our group reported the 
fi rst examples of asymmetric Ni(0)-mediated allylic amination 
chemistry.113 & 114 Here an N-protected-4-vinyloxazolin-2-one 
intermediate was generated via an enantioselective, intramo-
lecular allylic amination with a Ni(0)-BIPHEP catalyst system 
(Scheme 13). This was then transformed to L-vinylglycine. 
Scheme 13. Berkowitz et al.’s Ni(0)-mediated asymmetric allylic amination 
route. 
3.5. Methoxyvinylglycine (MVG)
An N-acylase mediated resolution of the Z- and E-isomers of 
MVG has been reported by Keith et al. (Route A, Scheme 14).115 
Alks116 introduced the following two modifi cations: (i) stereose-
Scheme 12. Trost’s DYKAT asymmetric allylic amination route. Scheme 14. Introducing the enol ether into E- and Z-MVG. 
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lective synthesis of N-Ac-(dl)-E-MVG methyl ester; (ii) thermal 
isomerization of the E- to Z-methyl ester (Route B, Scheme 14). 
Acylase resolves each geometric isomer of MVG, by selec-
tively deacetylating the L-amide115 (Scheme 15). 
Scheme 15. Enzymatic resolution of E- and Z-MVG. 
3.6. Rhizobitoxine
A concise synthesis of L-rhizobitoxine has been reported by Keith 
et al.117 (Scheme 16). The key transformation is a palladium(II)-
mediated trans-vinyl etherifi cation between N-Cbz-O-benzyl-D-
serinol and N-Cbz-L-MVG benzyl ester (E:Z  3:2). 
Scheme 16. Keith’s route to rhizobitoxine. 
3.7. 2-Amino-5-phosphono-4-pentenoic acid (APPA)
Kirihata has reported an asymmetric synthesis of E-APPA 
that strategically resembles Schöllkopf’s vinylglcyine syn-
thesis (Scheme 10), in that reaction of an aldehyde with the 
lithiated chiral bis-lactim ether 44, sets the α-stereochem-
istry in both approaches. Here, the use of acrolein results 
in an allylic center, which can then be coerced to under-
go Pd(II)-mediated allylic transposition, albeit in modest 
yield, to 64. Subsequent Arbuzov chemistry installs the ter-
minal phosphonate (Scheme 17). 
Scheme 17. Kirihata’s approach to E-APPA. 
4. Mechanism
4.1. Vinylic amino acids as conformationally constrained 
amino acid analogues?
As was mentioned earlier, Z-MVG, the geometric isomer of 
the natural product, inhibits methionine adensyl transferase, 
the enzyme responsible for the synthesis of SAM [(S)-ade-
nosylmethionine] from ATP and L-methionine. The crystal 
structure of this enzyme in complex with Z-MVG reveals the 
L-methionine binding site.41 & 42 This may be an example of 
an α-vinylic amino acid that serves as a good conformation-
ally constrained analogue of the saturated, and hence, inher-
ently more fl exible, natural substrate.
Similarly, perhaps E-APPA, also the geometric isomer of the nat-
ural product, acts as a reversible, tightly bound analogue of ho-
moserine phosphate in the active site of cystathionine γ-synthase 
(CGS).61 In this case as well, the X-ray crystal structure of the 
E–I complex, identifi ed the binding pocket of the phosphate side 
chain of the natural substrate. This suggests this vinylic amino 
acid with its E double bond confi guration mimics L-homoserine 
phosphate “frozen” in an extended conformation, that is especial-
ly productive for binding. The X-ray structure reveals that E-
APPA interacts with both the α-carboxylate and side chain phos-
phate binding pockets of CGS, in support of this view.
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In the sections to follow, we focus on inhibition mechanisms 
that appear to require enzymatic chemistry beyond the simple 
initial transimination reaction that is the canonical fi rst step in 
the binding of an amine substrate or substrate analogue to a 
PLP enzyme. In this sense, the mechanisms that follow high-
light the possibility for mechanism-based or enzyme-activated 
inhibition in this class of α-vinylic amino acids.
4.2. Mechanism A—vinylogous imidate formation
The fi rst mechanism that we wish to consider is likely favor-
able for the subclass of α-vinylic amino acids that features a 
heteroatom directly attached to the γ-carbon. This is the case 
for MVG, AVG, and rhizobitoxine (Fig. 4), for which the het-
eroatom is oxygen (i.e., enol ethers), though the same principle 
could apply to other heteroatoms. Although Rando fi rst carried 
out important mechanistic studies on the inhibition of aspartate 
aminotransferase by MVG many years ago, crystallograph-
ic information on the bound states of members of this vinylic 
amino acid class has only appeared much more recently.
As illustrated in Scheme 18, transimination from the rest-
ing state of the PLP enzyme would produce the external al-
dimine in which the α-vinylic functionality remains isolated 
from the π-system of the cofactor. As mentioned in the out-
set of this Report, the fi rst mechanistic step for a PLP de-
pendent transaminase, racemase, or eliminase is α-deproton-
ation. This produces a quinonoid intermediate in which the 
vinyl group is now fully conjugated with the PLP system. 
However, heteroatoms with donating lone pairs oppose one 
another at the ends of this system. Should protonation at C-
4′ ensue, this would have the effect of removing the N-1-
lone pair from the system, and this generates a vinylogous 
imidate. Such a ketimine is expected to benefi t from the ex-
cellent alkoxy electron donor/iminium electron acceptor jux-
taposition at the ends of this fi ve atom π-system. In other 
words, the π-delocalization energy inherent in the enol ether 
functionality of the inhibitor would have been signifi cantly 
enhanced through an enzyme-mediated azaallylic isomeriza-
tion, leading to this stable bound cofactor adduct. 
In fact, three X-ray crystal structures are available for AVG 
bound in PLP enzyme active sites (Fig. 6): apple ACC syn-
thase (PDB ID: 1M7Y; 1.6 Å),49 cystalysin (PDB ID: 1C7O; 
2.5 Å),46 and cystathionine β-lyase (PDB ID: 1CL2; 2.2 Å).44 
It should be noted that these enzymes are all eliminases, cat-
alyzing the α,γ-elimination of SAM to ACC, the α,β-elimi-
nation of cysteine to pyruvate (eventually) and the α,β-elim-
ination of cystathionine to cysteine, respectively. So, all 
inherently α-deprotonate their natural substrates. 
Scheme 18. Mechanism A: vinylogous imidate formation from γ-alkoxy-α-vinyl amino acids via PLP enzyme-catalyzed azallylic isomerization. 
Figure 6. Cofactor-AVG adducts bound in three PLP enzyme active sites (PDB codes: 1M7Y, 1C7O, and 1CL2, respectively). 
878 BERKOWITZ ET AL. IN TETRAHEDRON: ASYMMETRY 17 (2006)
The ACC synthase structure is the highest resolution of the 
three and also provides the best evidence for such a bound vi-
nylogous imidate. The dihedral angles across the Cγ–Cβ and Cβ–
Cα bonds are modeled at 177° and −146°, respectively, consis-
tent with such conjugation. Furthermore, the C4′–N–Cα–Cβ and 
C4′–N–Cα–carboxylate dihedrals are at 7° and −175°, respec-
tively, consistent with azallylic isomerization having occurred 
in the ACC synthase active site. Deviation from planarity in-
creases across Cβ–Cα as one moves from this structure to the 
CBL structure, but near planarity is retained across Cγ–Cβ. The 
cystalysin structure provides little evidence for such conjuga-
tion, but is also the lowest resolution of the three. Furthermore, 
the uncertainty inherent in E–I X-ray structures of this sort does 
not allow us to assign the double bond loci with certainty.
Nonetheless, the notion that γ-alkoxy-α-vinylic amino ac-
ids have a preference to form stabilized vinylogous imidate 
complexes with PLP would appear to be a chemically rea-
sonably postulate, worthy of further scrutiny in investiga-
tions of this amino acid subclass. Interestingly, in his early 
work with MVG, Rando observed a pronounced tendency of 
that amino acid to undergo azaallylic isomerization, even in 
Snell-type model reactions with PLP and Al3+,38 consistent 
with the notion of a thermodynamic driving force toward vi-
nylogous imidate formation in these adducts.
4.3. Mechanism B—Michael addition
Vinylglycine, the parent member of the α-vinyl amino acid 
family was isolated from a mushroom source in 1974.8 In 
the same year, Rando reported on its irreversible inactiva-
tion of a PLP enzyme, namely aspartate aminotransferase.17 
As was discussed earlier (Section 2.1), vinylglycine inacti-
vates a number of PLP enzymes, most of which are transami-
nases. Yet only in the past year has the nature of the covalent 
adduct formed between vinylglycine and one of its target en-
zymes lent itself to crystallographic characterization. This feat 
was accomplished with the enzyme ACC synthase.24 This en-
zyme normally engages its natural substrate, SAM in PLP al-
dimine linkage, followed by α-deprotonation. An unusual ex-
pulsion of the γ-leaving group, methylthioadenosine (MTA), 
is the normal next mechanistic step, leading to the formation 
of the strained cyclopropane ring of ACC.
As is discussed in greater detail below, L-vinylglycine is 
both an inhibitor and an abnormal (β,γ-elimination) product 
of this enzyme. A possible mechanism for the inactivation 
of ACC synthase with L-vinylglycine is depicted in Scheme 
19. The normal fi rst step, α-deprotonation is followed by C-
4′-protonation, as in Mechanism A, leading to an α,β-unsat-
urated iminium ion. This Michael acceptor is then captured 
by an active site nucleophile. The active site lysine is always 
a candidate for this role, as it is displaced in the initial tran-
simination step. This lysine residue then presumably remains 
in the vicinity of the resulting E–S or E–I adduct and of the 
complexes mechanistically derived therefrom. 
The 2005 Grütter/Kirsch crystal structure of ACC synthase in-
activated with L-vinylglycine is depicted in Figure 724 and re-
veals that, indeed, the active site lysine has formed a covalent 
bond with the γ-carbon of the inhibitor, as predicted. The ob-
servation of the three dimensional structure of this adduct ce-
ments perhaps the most widely accepted mechanism for ac-
tuation of the α-vinylic trigger. It also serves to rule out an 
alternative Michael addition pathway, whereby α-deproton-
Scheme 19. Mechanism B: inactivation of ACC synthase by L-vinylglycine via enzyme-catalyzed azaallyllic isomerization-Michael addition. 
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ation would be followed by γ-protonation, leading to an elec-
trophilic β-, rather than γ-carbon. 
Finally, the α-vinylic trigger found in the class of amino acids 
being reviewed here surely served as the inspiration for devel-
opment of vigabatrin (γ-vinyl-GABA), as a mechanism-based 
inactivator of GABA transaminase. Vigabatrin was developed 
by the Marion Merrell Dow group into an anti-epileptic drug of 
widespread use, particularly in Europe.118 It is probably fair to 
say that Vigabatrin was designed to act by a Michael addition 
mechanism analogous to Mechanism B (Scheme 19). Indeed, 
elegant mechanistic studies by the groups of Silverman119 and 
John120 pointed to such a mechanism as the primary one through 
which the drug inactivated its target enzyme, GABA transami-
nase. Pleasingly, the X-ray crystal structure appeared in 2004,121 
and served to validate this mechanism, again with the active site 
lysine serving as the Michael nucleophile (Fig. 7).
4.4. SMM: A natural “Pro-Form” of a vinylic amino acid?
The enzyme ACC synthase not only ended up serving as the 
showcase for the long-suspected Michael addition inactivation 
pathway of vinylglycine, it has also brought to light a novel 
mechanism by which Nature may biosynthesize vinylic amino 
acid progenitors. Namely, through a series of elegant studies 
from Kirsch et al., it has now been established that even sub-
tle changes in the vicinity of the γ-leaving group of the SAM 
substrate for ACC synthase can lead to profound changes in 
mechanistic partitioning in the active site. These fi ndings are 
illustrated schematically in Scheme 20. 
Kirsch fi rst studied the effect of the often ignored sulfur ste-
reocenter in SAM on ACC processing. Natural SAM has the SS 
stereochemistry, and undergoes errant β,γ-elimination to vinyl-
glycine only once for every 60 α,γ-eliminations to ACC.27 On 
the other hand, inversion of this sulfonium stereocenter alone, 
retaining the important L-methionine center, results in a parti-
tion reversal. β,γ-Elimination now predominates by a 2.5:1 ra-
tio over the usual α,γ-elimination.26 This is really a remark-
able observation, especially when one considers that these two 
substrates not only share the same α-stereochemistry, but have 
chemically exactly the same leaving group, MTA.
Perhaps led by this result, Kirsch et al. then decided to exam-
ine the behavior of L-(S)-methylmethionine (SMM), a ubiqui-
tous component of the tissues of fl owering plants; SMM un-
dergoes no α,γ-elimination whatsoever with ACC synthase. 
Instead, a small amount of transamination to the ketone is ob-
served. Otherwise, one sees almost exclusive conversion of 
SMM to vinylglyine in this active site.
Figure 7. Evidence of Mechanism B for L-vinylglycine with ACC synthase (PDB 1YNU) and for vigabatrin with GABA transaminase (PDB 1YHW). 
Scheme 20. Fate of SAM and analogues in the ACC synthase active site. 
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Furthermore, there is 15-fold greater probability for SMM-de-
rived “vinylglycine” to inactivate, when compared with SAM-
derived “vinylglycine.” This probably refl ects a greater per-
centage of enamine tautomer (i.e., γ-protonation) in the SAM 
case, leading to more α-ketobutyrate product, as opposed to C-
4′-protonation, which would lead to the inactivating Michael 
acceptor. These studies raise the intriguing possibility that L-
SMM is a natural, masked progenitor of L-vinylglycine, itself 
a masked enzyme inactivator. Why two layers of unmasking? 
One possibility lies in the relatively broad spectrum PLP-en-
zyme inactivation profi le of vinylglycine itself. Perhaps Na-
ture has biosynthesized SMM as a way of targeting specifi c 
formation of vinylglycine to the ACC active site.
5. Conclusion
The known α-vinylic amino acids comprise of a diverse set of 
structurally and mechanistically fascinating natural products, 
many of which act as inhibitors of PLP enzymes, though ad-
ditional members of the class are surely yet to be discovered. 
The parent member of the family, vinylglycine, has drawn the 
most attention, as it is both generated in a number of active 
sites, and serves as a broad spectrum inactivator. Its covalent 
mechanism of attachment to ACC synthase via Michael addi-
tion was just recently revealed by X-ray crystallography.
From a medicinal chemistry point of view, vinylglycine 
also served to inspire the development of Vigabatrin, an es-
tablished drug for the prevention of epileptic seizures, and a 
possible candidate for future treatment of drug addiction.122, 
123 and 124 Interestingly, X-ray crystallographic studies on its 
GABA transaminase target now reveal as close a parallel be-
tween mechanisms of the designed drug and the natural prod-
uct as could ever have been imagined.
From a synthetic point of view, vinylglycine has also been at 
the center of this amino acid class, because of its high val-
ue as a chiral synthetic building block toward the synthe-
sis of alkaloids, azasugars, and novel amino acids. This con-
tinues to motivate organic chemists to develop asymmetric 
routes to each antipode of vinylglycine, from chiron based, 
to chiral auxiliary based, to catalytic asymmetric approaches. 
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